Overview
Infinium Pharmachem Limited specializes in the manufacturing of iodine-based pharmaceutical intermediates, catering to diverse industries such as pharmaceuticals, biotechnology, and specialty chemicals.
The company is strategically expanding its iodine value chain by venturing into the contrast media segment, aiming for substantial revenue from sales beginning FY26, and targeting Rs 300 Cr in revenue in 3-5 years.
A significant strategic joint venture with IBL Elements secures long-term iodine supply, enhancing control and cost effectiveness with a 30-year agreement for captive sourcing of ~120 MT/year.
Infinium's recent strategic partnership with K Sakai & Company in Japan aims to tap into the unexplored iodine derivatives market across several sectors, expanding its global footprint.
Despite a challenging market, Infinium achieved revenue growth with a 5-year CAGR of 32.1%, alongside a robust 5-year EBITDA CAGR of 43.39%, showcasing its operational efficiency.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs
- Market Cap
338 Cr
- Volatility
Moderate Risk
- P/E Ratio
38.8
- Industry P/E
56.7
- PEG Ratio
2.5
- P/B Ratio
3.1
- 52W High
337.00
- 52W Low
202.05
Financial Ratios
Sales CAGR
- 1Y
- 14.78%
- 3Y
- 22.74%
- 5Y
- 30.60%
- 10Y
- —
Profit CAGR
- 1Y
- -31.83%
- 3Y
- 15.45%
- 5Y
- 52.76%
- 10Y
- —
ROE
- TTM
- 8.14%
- 3Y
- 13.86%
- 5Y
- 16.42%
- 10Y
- —
ROCE
- TTM
- 13.29%
- 3Y
- 20.56%
- 5Y
- 23.06%
- 10Y
- —
Technicals
Oscillators
Neutral
Bearish
5
Neutral
7
Bullish
2
Overall
Bearish
Bearish
20
Neutral
7
Bullish
19
Moving Averages
Bullish
Bearish
15
Neutral
0
Bullish
17
Peers
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
217.00 | 338 Cr | 38.75 | 3.09 | 0.00 | 8.14 | 13.29 | 5.02 | |
303.00 | 297 Cr | 50.42 | 4.10 | 0.00 | 0.00 | 0.00 | 2.46 | |
10.99 | 267 Cr | 14.44 | 1.25 | 0.00 | 7.77 | 8.53 | 5.49 | |
70.19 | 200 Cr | 66.22 | 1.38 | 0.00 | 2.41 | 5.22 | 1.17 | |
50.60 | 187 Cr | -10.33 | 0.00 | 0.00 | 46.67 | -53.26 | -15.44 | |
294.00 | 182 Cr | 62.03 | 4.23 | 0.00 | 4.47 | 7.31 | 1.55 | |
159.00 | 167 Cr | 22.91 | 2.98 | 0.00 | 8.67 | 10.26 | 3.81 |
Price Chart Comparison
Documents
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY24
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
